EPO and Hypertension: Daprodustat and roxadustat showed reduced hypertension rates (daprodustat OR: 0.79; 95% CrI: 0.59 to 1.04), supporting the hypothesis that HIF-PHIs maintain more physiological erythropoietin levels, avoiding supraphysiologic peaks seen with ESAs [21].